BMO Capital Markets reaffirmed their hold rating on shares of Gilead Sciences (NASDAQ:GILD) in a report published on Wednesday morning.

GILD has been the topic of several other reports. Berenberg Bank set a $96.00 price objective on shares of Gilead Sciences and gave the company a buy rating in a research report on Thursday, October 19th. Royal Bank of Canada initiated coverage on shares of Gilead Sciences in a research report on Thursday, September 14th. They issued an outperform rating and a $94.00 price objective on the stock. JPMorgan Chase & Co. set a $85.00 price objective on shares of Gilead Sciences and gave the company a buy rating in a research report on Wednesday, October 25th. Credit Suisse Group reissued a buy rating and issued a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, December 7th. Finally, Zacks Investment Research lowered shares of Gilead Sciences from a hold rating to a sell rating in a research report on Wednesday, December 27th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. Gilead Sciences has an average rating of Buy and a consensus price target of $85.03.

Gilead Sciences (NASDAQ GILD) opened at $74.52 on Wednesday. The firm has a market cap of $98,130.00, a PE ratio of 8.48, a PEG ratio of -1.57 and a beta of 1.13. Gilead Sciences has a 1 year low of $63.76 and a 1 year high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company’s revenue was down 13.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.75 earnings per share. sell-side analysts predict that Gilead Sciences will post 8.53 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were paid a $0.52 dividend. The ex-dividend date was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.79%. Gilead Sciences’s payout ratio is currently 23.66%.

In other news, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the completion of the sale, the insider now owns 3,070,099 shares in the company, valued at $230,656,537.87. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 461,666 shares of company stock worth $34,072,567. 1.30% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of GILD. FMR LLC boosted its position in Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after buying an additional 258,005 shares during the period. Investment Centers of America Inc. boosted its position in Gilead Sciences by 7.2% during the 1st quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock worth $1,979,000 after buying an additional 1,958 shares during the period. Vanguard Group Inc. boosted its position in Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after buying an additional 2,148,697 shares during the period. Northern Trust Corp boosted its position in Gilead Sciences by 0.7% during the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after buying an additional 116,780 shares during the period. Finally, Fagan Associates Inc. boosted its position in Gilead Sciences by 2.6% during the 2nd quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock worth $2,341,000 after buying an additional 845 shares during the period. Institutional investors own 75.94% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.watchlistnews.com/gilead-sciences-gild-earns-hold-rating-from-bmo-capital-markets/1797339.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.